Product
LYB005
1 clinical trial
2 indications
Indication
Respiratory Syncytial VirusIndication
Respiratory Syncytial Virus InfectionClinical trial
A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and OlderStatus: Not yet recruiting, Estimated PCD: 2025-02-01